Does insurance cover Wegovy in New York?

If you’re considering medications like Wegovy, Ozempic, or Mounjaro for weight loss, one question likely dominates your mind: Will my insurance actually pay for this?

The short answer: it depends—on your insurance type, your diagnosis, and increasingly, where you live. As of late 2025, the landscape for weight loss medication coverage has become more complicated than ever, with some states cutting coverage entirely while manufacturers scramble to lower prices. Whether you’re navigating commercial insurance, Medicare, or Medicaid, understanding your coverage options can save you thousands of dollars—or help you find affordable alternatives.

Let’s break down exactly what you need to know about insurance coverage for these breakthrough weight loss medications.

Understanding GLP-1 Medications: What They Are and Who They’re For

Before diving into insurance details, it’s important to understand what we’re talking about. GLP-1 receptor agonists are a class of medications originally developed for Type 2 diabetes that have shown remarkable effectiveness for weight loss:

• Wegovy (semaglutide): FDA-approved specifically for chronic weight management in adults with obesity or overweight with related health conditions
• Ozempic (semaglutide): FDA-approved for Type 2 diabetes, though often prescribed off-label for weight loss
• Mounjaro (tirzepatide): FDA-approved for Type 2 diabetes; its weight-loss formulation is marketed as Zepbound

These medications work by mimicking hormones that regulate appetite and blood sugar, leading to significant weight loss—often 15-20% of body weight over a year. But there’s a catch: they’re expensive, with list prices exceeding $1,000 per month.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Commercial Insurance Coverage Reality

If you have private insurance through your employer or the marketplace, coverage for these medications varies dramatically based on whether you’re using them for diabetes or weight loss.

Coverage for Diabetes: Generally Available

When prescribed for Type 2 diabetes, Ozempic and Mounjaro are typically covered by commercial insurance plans. Diabetes treatment is considered an essential health benefit under the Affordable Care Act, so insurers generally include these medications on their formularies—though usually on higher tiers (Tier 3 or specialty tiers) with significant copays or coinsurance.

Most plans require prior authorization to confirm:

• A documented Type 2 diabetes diagnosis
• Evidence that you’ve tried first-line medications like metformin
• Clinical justification for choosing a GLP-1 over other diabetes treatments

Even with insurance, expect to pay anywhere from $25 to several hundred dollars per month depending on your plan’s cost-sharing structure.

Coverage for Weight Loss: The Challenge

Here’s where it gets tricky. Many commercial insurers exclude or severely restrict coverage for medications prescribed solely for weight loss, even FDA-approved ones like Wegovy. Why? Cost. With monthly list prices around $1,350 for Wegovy, insurers worry about the budget impact if millions of Americans with obesity seek coverage.

According to a 2024 KFF analysis, weight loss drug coverage in commercial plans is far from universal. Many employers opt out of covering anti-obesity medications as ‘optional’ benefits. For plans that do cover Wegovy, expect stringent requirements:

Common prior authorization criteria include:

• BMI of 30 or higher (or 27+ with weight-related comorbidities like hypertension or sleep apnea)
• Documentation of at least 6 months of supervised diet and lifestyle modification attempts
• Proof that previous weight loss efforts failed to achieve meaningful results
• Sometimes, evidence that you tried older, cheaper weight-loss medications first

Aetna’s clinical policy, for example, requires patients to have engaged in ‘a documented, multi-component program of diet, physical activity and behavioral modification for at least 6 months prior to using drug therapy.’ These programs must include reduced-calorie diets and behavioral counseling.

Even if approved, coverage is often time-limited. Insurers may approve an initial 3-6 month trial, then require re-authorization proving you’ve achieved at least 5% weight loss to continue coverage.

Medicare Coverage: Limited and Specific

Medicare Part D does not cover medications for weight loss—period. This exclusion is written into federal law (the Social Security Act specifically excludes ‘drugs used for weight loss’ from Part D coverage).

However, there’s an important exception: Medicare will cover GLP-1 medications when prescribed for their other FDA-approved indications. In March 2024, Medicare began covering Wegovy for cardiovascular risk reduction in obese patients with established heart disease. This means if you have obesity and documented cardiovascular disease, your Medicare Part D plan may cover Wegovy—but only for heart protection, not weight loss per se.

For Ozempic and Mounjaro, Medicare covers them when prescribed for Type 2 diabetes, similar to commercial insurance. The drug is placed on Part D formularies as a diabetes treatment, typically requiring prior authorization and step therapy (trying metformin or other oral agents first).

Some Medicare Advantage plans have begun offering limited coverage for anti-obesity medications in 2025, but this varies by plan and remains the exception rather than the rule.

Medicaid Coverage: A Patchwork Across States

Medicaid coverage for weight loss medications is perhaps the most confusing area because it varies dramatically by state—and is rapidly changing.

The Federal Framework

Federal law allows states to exclude ‘drugs used for weight loss’ from Medicaid coverage. As of late 2024, only about 13 states chose to cover GLP-1 medications for obesity treatment. Those that do cover these drugs almost always impose strict prior authorization requirements similar to commercial insurance: high BMI thresholds, documented comorbidities, proof of lifestyle intervention failure, and periodic re-evaluation.

State-by-State Coverage Status (Priority States)

California (Medi-Cal): In a significant policy reversal, California announced in December 2025 that it will stop covering Wegovy, Saxenda, and Zepbound for weight loss effective January 1, 2026. The state cited budget constraints—covering these expensive medications was costing hundreds of millions annually. Prior to this cut, California did cover these drugs with strict criteria (BMI ≥30 or ≥27 with comorbidities, 6-month supervised diet requirement). Pediatric patients may still access coverage under EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) provisions.

Texas: Texas Medicaid does not cover any anti-obesity medications for adults age 21 and over. The state explicitly excludes Wegovy, Saxenda, and similar drugs from its formulary. For members under 21, case-by-case exceptions might be requested through EPSDT, but adult coverage is categorically prohibited.

Florida: Florida Medicaid does not cover weight loss drugs, utilizing the optional federal exclusion. Only diabetes-indicated GLP-1s like Ozempic are covered, and only when prescribed for Type 2 diabetes.

New York: New York’s Medicaid program does cover Wegovy with prior authorization. Patients must meet FDA labeling criteria: BMI ≥30 or ≥27 with comorbidities, documented lifestyle modification attempts, and age ≥18. Quantity limits apply (typically 4 pens per 28 days), and ongoing authorization requires demonstrating weight loss progress.

Pennsylvania: Pennsylvania Medicaid began covering Wegovy and other newer weight loss medications in 2023 with comprehensive prior authorization requirements. Patients need BMI ≥30 (or ≥27 with at least one weight-related comorbidity), documented diet and exercise attempts, and for those with diabetes or prior GLP-1 use, must try a preferred diabetes GLP-1 first. However, following California’s lead, Pennsylvania announced in December 2025 that it will end coverage for GLP-1 weight loss medications in January 2026 due to budget pressures.

Illinois: Illinois Medicaid does not cover Wegovy or other anti-obesity medications as of 2025. While the state expanded coverage for state employees in 2023, this did not extend to Medicaid enrollees.

The trend is clear: even states that initially embraced coverage are now pulling back due to fiscal concerns. The cost of covering these medications for eligible Medicaid populations—which includes millions of Americans with obesity—has proven unsustainable for many state budgets.

Why Insurance Denies Coverage: Common Reasons

Understanding why claims get denied can help you avoid common pitfalls or prepare stronger appeals:

1. Medical necessity not established: Your BMI doesn’t meet the threshold, or you lack documented comorbidities required by your plan’s criteria.

2. Insufficient documentation: No records of supervised diet/exercise programs, missing physician notes, or incomplete weight history.

3. Step therapy not completed: For diabetes medications, you haven’t tried required first-line treatments. For weight loss, you haven’t attempted lifestyle interventions or older weight-loss medications your plan requires.

4. Off-label use: Requesting Ozempic or Mounjaro for weight loss when you don’t have diabetes. Insurers will only cover these for their FDA-approved diabetes indication unless your plan explicitly covers off-label obesity treatment.

5. Plan exclusion: Your specific insurance policy excludes coverage for weight loss drugs entirely, regardless of medical justification. This is common in employer-sponsored plans that opted out of obesity treatment coverage.

Navigating the Prior Authorization Process

If your insurance does cover GLP-1 medications for your situation, be prepared for the prior authorization gauntlet. Here’s what typically happens:

Step 1: Provider submits PA request with documentation including:

• Current BMI and weight history
• Comorbidity documentation (lab results, diagnoses)
• Records of previous weight loss attempts
• Treatment plan and monitoring strategy

Step 2: Insurance review (typically 5-7 business days for standard requests)

Step 3: Approval, denial, or request for additional information

Timeline expectations: Initial decisions usually come within a week, though this can extend to 2-3 weeks during busy periods or if additional documentation is needed.

The Appeals Process: When and How to Fight a Denial

If your initial request is denied and you believe you meet the criteria, don’t give up. Appeal success rates vary, but patients who truly meet clinical criteria often succeed on first appeal with proper documentation.

Strengthening your appeal:

• Provide comprehensive physician letter explaining medical necessity
• Include complete weight history with dates and documented attempts
• Highlight specific comorbidities and their severity
• Reference your plan’s specific coverage criteria and explain how you meet each requirement
• Include peer-reviewed research supporting the medication’s effectiveness for your situation

Appeals for severe obesity (BMI ≥35) with multiple comorbidities tend to have higher success rates, especially when cardiovascular risk factors are present.

Self-Pay Options: What If Insurance Won’t Cover It?

For many Americans, insurance coverage remains out of reach—either due to outright exclusions or inability to meet strict criteria. Fortunately, pricing options have improved dramatically in late 2025.

Manufacturer Programs and Discounts

GoodRx Partnership with Novo Nordisk:
In November 2025, GoodRx launched an industry-leading program offering:

• Wegovy or Ozempic for $199/month for the first two months
• $349/month ongoing for most doses (compared to ~$1,350 list price)
• Available at nearly all U.S. pharmacies

This represents a 70% discount off list prices and makes these medications accessible to many cash-paying patients for the first time.

Novo Nordisk Direct Programs:

• Wegovy Access Program: $349/month self-pay price through NovoCare (down from previous $499)
• Savings Card for insured patients: Up to $225 off per month for commercially insured patients whose plans cover the medication (potentially reducing copay to $0)

Eli Lilly Programs:

• Zepbound self-pay vials: $299-$449 per month depending on dose (single-dose vials through LillyDirect)
• Mounjaro Savings Card: $25 per month for commercially insured Type 2 diabetes patients (covers up to ~$500 of the cost)

Patient Assistance Programs

Both Novo Nordisk and Eli Lilly offer patient assistance programs for uninsured or underinsured individuals who meet income criteria (typically household income below 400% of federal poverty level). These programs can provide medications at little or no cost for qualifying patients for up to one year.

Important Note on Compounded Medications

You may encounter offers for compounded semaglutide or tirzepatide at lower prices through telehealth or wellness clinics. Exercise extreme caution. These formulations are not FDA-approved and may carry quality and safety risks. The FDA and manufacturers have warned about counterfeit or improperly compounded versions. If cost is prohibitive, explore the manufacturer programs above rather than unregulated alternatives.

How Klarity Health Can Help Navigate Your Options

Understanding insurance coverage is just one piece of the puzzle. At Klarity Health, we recognize that navigating weight management treatment can feel overwhelming—especially when insurance barriers stand in your way.

Through our telehealth platform, licensed healthcare providers can:

• Assess your candidacy for GLP-1 medications based on comprehensive health evaluation
• Provide documentation needed for insurance prior authorization requests
• Create personalized treatment plans that align with insurance requirements
• Offer both insured and cash-pay options with transparent pricing

What sets Klarity Health apart is our provider availability—you can often connect with a qualified healthcare provider within 24-48 hours via secure video consultation. Whether your insurance covers weight loss medications or you’re exploring self-pay options, our providers work with you to find an affordable path forward.

For patients whose insurance covers GLP-1 medications, Klarity accepts both insurance and cash payment. For those facing coverage denials or exclusions, our transparent cash-pay pricing ensures you know exactly what to expect—no surprise bills.

Telehealth and Insurance: What’s Covered?

One bright spot in this complex landscape: most insurance plans now cover telehealth visits for weight management at the same level as in-person consultations.

Since the COVID-19 pandemic, telehealth coverage has become standard. More than 40 states have telehealth parity laws requiring private insurers to cover virtual services equivalently to in-person care. This means:

• Covered services: Initial consultations, follow-up visits, nutrition counseling, behavioral therapy for weight management
• Same copays/coinsurance: What you’d pay for an office visit typically applies to telehealth
• Preventive benefits: Under the ACA, obesity screening and counseling is a required preventive service with no cost-sharing for most plans

Important considerations:

• Verify the telehealth provider is in-network (though many platforms now have broad network agreements)
• Most plans require live video for coverage (phone-only visits may not qualify)
• Even if the telehealth visit itself is cash-pay, prescriptions written can still be covered by your insurance pharmacy benefit

The expanded acceptance of telehealth has dramatically improved access to weight management care, particularly for patients in rural areas or those with mobility limitations.

State-Specific Considerations and Regional Differences

Where you live significantly impacts your coverage options:

States with more comprehensive Medicaid coverage (as of early 2025, though this is changing):

• New York
• Massachusetts (with restrictions)
• Connecticut (limited to specific cases)
• Minnesota
• Vermont

States with no Medicaid coverage:

• Texas, Florida, Illinois
• Most Southern and Midwestern states

States cutting coverage in 2026:

• California
• Pennsylvania

For commercial insurance, while coverage doesn’t vary by state per se, regional employer practices do. Large employers in tech hubs and progressive states are more likely to include comprehensive obesity treatment benefits, while employers in other regions may exclude these medications entirely.

Comparing Your Coverage Options: A Decision Framework

Practical Steps: What to Do Right Now

If you’re considering GLP-1 medications for weight loss or diabetes management:

1. Check your specific plan’s formulary
Don’t assume based on your insurance type—log into your insurance portal and search the drug formulary, or call member services to ask specifically about Wegovy, Ozempic, or Mounjaro coverage and requirements.

2. Document everything
Start keeping records now:

• Weekly weight measurements
• Diet and exercise logs
• Medical appointments related to weight or related conditions
• Lab results (A1c, cholesterol, blood pressure)

3. Have the conversation with your provider
Discuss whether GLP-1 medications are appropriate for your situation and whether your provider believes you meet insurance criteria. They can often preview what documentation will be needed.

4. Explore all pricing options
Before assuming you can’t afford these medications:

• Check GoodRx pricing (often $349/month or less)
• Ask about manufacturer savings cards
• Inquire about patient assistance programs if uninsured
• Compare pharmacy prices—they vary significantly

5. Consider telehealth options
If access to weight management specialists is limited in your area, platforms like Klarity Health connect you with licensed providers who understand insurance requirements and can provide the documentation you need—often with shorter wait times than traditional practices.

The Future of Coverage: What’s Coming

The landscape for GLP-1 coverage continues to evolve rapidly:

Potential Medicare expansion: There’s bipartisan Congressional support for allowing Medicare to cover anti-obesity medications more broadly, though budget concerns remain a major obstacle. The ‘Treat and Reduce Obesity Act’ has been introduced in multiple sessions but hasn’t passed.

State Medicaid decisions: Following California and Pennsylvania’s lead, expect more states to reconsider obesity drug coverage in 2026-2027 due to budget pressures. Conversely, if federal funding changes or drug prices drop significantly, some states might expand access.

Biosimilars on the horizon: While no generic GLP-1s are available yet (patents extend into the 2030s), several biosimilar versions are in development. When these reach the market, prices could drop significantly, potentially changing insurers’ cost-benefit calculations.

Employer trends: As real-world data demonstrates that treating obesity reduces long-term healthcare costs, more employers may include comprehensive obesity treatment benefits—or conversely, continue to exclude them if short-term budget concerns dominate.

When Coverage Isn’t an Option: Alternative Approaches

If insurance coverage remains elusive and self-pay pricing is beyond your budget, remember that GLP-1 medications aren’t the only path to meaningful weight loss:

Other prescription options: Older weight loss medications like phentermine, orlistat, or combination therapies (Qsymia, Contrave) cost $30-$150 per month and are more widely covered by insurance.

Comprehensive lifestyle programs: Many insurance plans cover obesity counseling, nutrition therapy, and behavioral programs at little or no cost. While medications can accelerate results, sustainable weight loss ultimately requires lifestyle changes that these programs support.

Emerging treatments: New anti-obesity medications are in development, and treatment paradigms continue to evolve. Staying engaged with a healthcare provider ensures you’re aware of new options as they become available.

Making an Informed Decision

The question ‘Does insurance cover weight loss medication?’ doesn’t have a simple yes or no answer in 2025. Coverage depends on your specific insurance type, the medication, your medical situation, and increasingly, where you live. But with manufacturer discount programs bringing costs down to $199-$349 per month for self-pay patients, these medications are becoming accessible even without insurance coverage.

Whether you’re navigating prior authorization requirements, appealing a denial, or exploring self-pay options, understanding the landscape empowers you to advocate for yourself effectively. And with telehealth expanding access to knowledgeable providers, you don’t have to navigate this complexity alone.

At Klarity Health, we believe everyone deserves access to effective weight management solutions, regardless of insurance status. Our providers are available to help you explore all your options—from insurance coverage to affordable self-pay alternatives—and create a treatment plan that works for your health goals and budget.

Ready to explore your weight loss medication options? Connect with a licensed Klarity Health provider today to discuss whether GLP-1 medications are right for you and learn about coverage and pricing options specific to your situation.

📅 RESEARCH CURRENCY STATEMENT (Verified as of December 17, 2025)

References

1. Aetna Clinical Policy Bulletin – Weight Loss (BMI 35) GIP-GLP-1, GLP-1 Agonists PA with Limit. May 2024. Available at: www.aetna.com

2. California Department of Health Care Services (DHCS) – Medi-Cal Rx Bulletin: GLP-1 medications for weight loss will no longer be covered by Medi-Cal. December 2025. Available at: www.cmadocs.org

3. Forbes Healthcare – Cohen J. Coverage of Weight Loss Drugs by Medicaid Plans Continues to Lag. August 7, 2025. Available at: www.forbes.com

4. Kaiser Family Foundation (KFF) – Medicaid Coverage of and Spending on GLP-1s. Issue Brief, November 4, 2024. Available at: www.kff.org

5. GoodRx Press Release – GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic and Wegovy. November 17, 2025. Available at: www.businesswire.com

Formularies checked: Aetna Clinical Policy (May 2024), Cigna Formulary (April 2024), Kaiser Permanente update (January 2025), Texas VDP criteria (March 2023), Pennsylvania Medicaid bulletin (August 2024). Medicaid formularies verified: California DHCS (December 2025), Texas HHSC (March 2023), Florida (no Medicaid coverage per federal exclusion), New York NYRx PDL (October 2025), Pennsylvania DHS (December 2025), Illinois HFS (no coverage as of 2025). GoodRx prices as of: December 2025 – Novo Nordisk/NovoCare program (effective November 2025), GoodRx press release (November 17, 2025), Lilly pricing updates (December 2025).

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499